Abstract

This study investigated the synergistic cytotoxic effect of cisplatin and nimotuzumab combination in neuroblastoma cells and their impact on EGFR/MEK/ERK signaling. Human neuroblastoma cells (SH-SY5Y) were treated with cisplatin (1, 3, and 10 µM), nimotuzumab (10 µM), and their combinations (1 µM Cis + 10 µM NMTZ, 3 µM Cis + 10 µM NMTZ, and 10 µM Cis + 10 µM NMTZ) for 48 h. Cell viability was assessed using a proliferation assay, while western blot analysis measured protein expression levels. Quantitative RT-PCR was performed to determine EGFR mRNA expression. Cisplatin monotherapy reduced cell viability with survival rates of 82% (1 µM), 71% (3 µM), and 60% (10 µM) (p

Key words: Neuroblastoma, cisplatin, nimotuzumab, combination therapy